Retatrutide is a novel triple-hormone receptor agonist developed by Eli Lilly, targeting GIP, GLP-1, and glucagon receptors simultaneously. Clinical trials have demonstrated substantial weight loss outcomes exceeding those of semaglutide and tirzepatide in head-to-head comparisons. As of recent data, it remains in Phase 3 development and has not yet received FDA approval for obesity treatment. The compound represents the next generation of incretin-based therapies with mechanisms aimed at maximizing calorie burn while regulating appetite and glucose metabolism.
Retatrutide
Price range: £60.00 through £80.00
| Amount | 10mg, 20mg |
|---|
Related products
-
TB-500
Price range: £70.00 through £110.00Select options This product has multiple variants. The options may be chosen on the product page -
Epitalon
Price range: £50.00 through £120.00Select options This product has multiple variants. The options may be chosen on the product page -
Tesamorelin
Price range: £90.00 through £130.00Select options This product has multiple variants. The options may be chosen on the product page -
Ipamorelin
Price range: £50.00 through £60.00Select options This product has multiple variants. The options may be chosen on the product page